Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

Introduction: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and qualit...

Full description

Bibliographic Details
Main Authors: Banerjee, S. (Author), Colombo, M.J (Author), Elbez, Y. (Author), Foley, P. (Author), Gooderham, M. (Author), Gordon, K.B (Author), Gottlieb, A.B (Author), Kisa, R.M (Author), Menter, M.A (Author), Merola, J.F (Author), Morita, A. (Author), Napoli, A.A (Author), Papp, K.A (Author), Puig, L. (Author), Strober, B. (Author), Thaçi, D. (Author), Wei, L. (Author), Ye, J. (Author)
Format: Article
Language:English
Published: Adis 2022
Subjects:
adult
Article
body surface
Body surface area
clinical outcome
controlled study
Dermatology Life Quality Index
deucravacitinib
disease severity
drug dose comparison
female
human
Humans
major clinical study
male
phase 2 clinical trial
phototherapy
post hoc analysis
protein kinase TYK2
Psoriasis
Psoriasis Area and Severity Index
psoriasis vulgaris
quality of life
Quality of life
randomized controlled trial
treatment response
TYK2
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items